Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01890265 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Pamrevlumab
DRUG: Placebo
DRUG: Sub-Study: Pirfenidone
DRUG: Sub-Study: Nintedanib

Sponsor

Kyntra Bio